\nTriSalus Life Sciences\u00ae<\/sup>, Inc. (\u201cTriSalus\u201d or the \u201cCompany\u201d), an oncology company in the process of going public through a business combination transaction (the \u201cBusiness Combination\u201d) with MedTech Acquisition Corporation (Nasdaq: MTAC) (\u201cMedTech\u201d or \u201cMTAC\u201d), today announced that James \u201cJim\u201d Alecxih has joined the Company in the newly created role of President, Device Technology Business.\n<\/p>\n
\nMr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus\u2019 TriNav\u00ae<\/sup> Infusion System<\/a> (\u201cTriNav\u00ae<\/sup>\u201d), including device engineering, device quality, sales, marketing, and market access. Used in over 17,000 procedures, TriNav\u00ae<\/sup> is a FDA-cleared therapy delivery technology that leverages the Pressure-Enabled Drug Delivery\u2122 (\u201cPEDD\u2122\u201d) method to improve therapy uptake and tumor response.\n<\/p>\n \n\u201cJim\u2019s experience in successfully manufacturing, commercializing and bringing to market novel medical devices is ideally suited to the work we are doing at TriSalus to improve treatments for patients with liver and pancreatic cancers,\u201d said Mary Szela, CEO and President of TriSalus. \u201cOur TriNav\u00ae<\/sup> Infusion System is in its growth stage, and we are confident that Jim will help us capture the opportunities ahead to take the Company to the next level. We welcome Jim to TriSalus and I look forward to working together to improve the lives of patients through our disruptive technology.\u201d\n<\/p>\n \nJim Alecxih commented, \u201cI am excited to join TriSalus during this pivotal period for the Company. Over the course of my career, I\u2019ve worked with a number of innovative medtech companies, and I was drawn to TriSalus because of the Company\u2019s unique platform and the ways in which its TriNav\u00ae<\/sup> system can improve therapeutic delivery and tumor targeting. I look forward to collaborating with Mary Szela, Dr. Katz and the rest of the team to enable better cancer treatment for patients and drive enhanced outcomes across multiple indications.\u201d\n<\/p>\n \nPrior to joining TriSalus, Mr. Alecxih served as President and CEO of ViveBio Scientific, a medical device company focused on blood transport and storage systems. Previously, he served as Chief Commercial Officer of ViewRay, an early-stage radiation oncology company, where he managed global sales, marketing, and training. He also spent 15 years at Intuitive Surgical, Inc., maker of the da Vinci surgical and Ion endoluminal systems, where he led an 850-person sales organization across the U.S. and Canada and exceeded revenue targets for 51 consecutive quarters.\n<\/p>\n About TriSalus and Its Proposed Business Combination with MedTech<\/b><\/p>\n \nTriSalus is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.\n<\/p>\n \nTriSalus\u2019 proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its drug delivery technology with immunotherapeutics. The TriSalus platform comprises the TriNav\u00ae<\/sup> Infusion System and SD-101, a class C toll-like receptor 9 (TLR9) agonist. TriNav\u00ae<\/sup> is an FDA-cleared device that is designed to administer established and emerging therapeutics. SD-101, the Company\u2019s investigational TLR9 agonist, is being delivered via TriNav\u00ae<\/sup> to selected sites, including tumors in the liver. TriNav\u00ae<\/sup> is the latest TriSalus asset for the proprietary PEDD\u2122 method of administration which has been shown to overcome intratumoral pressure through modulation of pressure and flow to increase delivery of therapeutic agents.\n<\/p>\n \nAs previously announced on November 14, 2022, TriSalus has entered into a definitive merger agreement with MedTech (the \u201cMerger Agreement\u201d), a publicly traded special purpose acquisition company in connection with the proposed business combination and related transactions between the parties. Upon the closing of the transaction, which is expected to occur in the second quarter of 2023, the combined company will be a publicly traded company and its common stock is expected to be listed on the NASDAQ Stock Exchange under the ticker \u201cTLSI.\u201d The transaction is subject to the satisfaction of the necessary regulatory approvals and customary closing conditions, including the approval of MedTech\u2019s shareholders.\n<\/p>\n About MedTech Acquisition Corporation<\/b><\/p>\n \nMedTech is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.\n<\/p>\n Changes and Additional Information in Connection with SEC Filing<\/b><\/p>\n \nThe information in this communication has not been reviewed by the U.S. Securities and Exchange Commission (\u201cSEC\u201d) and certain information may not comply in certain respects with SEC rules. MTAC filed with the SEC a registration statement on Form S-4 (File No. 333-269138) (as amended, the \u201cRegistration Statement\u201d), which includes a proxy statement\/prospectus of MTAC that will be both the proxy statement to be distributed to holders of MTAC\u2019s common stock in connection with its solicitation of proxies for the vote by MTAC\u2019s stockholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the Business Combination. The Registration Statement is not yet effective. The Registration Statement, including the proxy statement\/prospectus contained therein, when it is declared effective by the SEC, will contain important information about the Business Combination and the other matters to be voted upon at a meeting of MTAC\u2019s stockholders to be held to approve the Business Combination and other matters (the \u201cSpecial Meeting\u201d). MTAC may also file other documents with the SEC regarding the Business Combination. MTAC stockholders and other interested persons are advised to read, when available, the Registration Statement, including the proxy statement\/prospectus contained therein, as well as any amendments or supplements thereto, because they will contain important information about the Business Combination. When available, the definitive proxy statement\/prospectus will be mailed to MTAC stockholders as of a record date to be established for voting on the Business Combination and the other matters to be voted upon at the Special Meeting.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis communication contains certain \u201cforward-looking statements\u201d within the meaning of the United States federal securities laws regarding MTAC\u2019s or TriSalus\u2019 expectations, hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the potential of TriSalus\u2019 proprietary PEDD\u2122 method to improve therapy uptake and tumor response and (ii) expectations for continuing program development and capturing future sales opportunities. These forward-looking statements generally are identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201cwould,\u201d \u201cwill\u201d and similar expressions or the negative or other variations of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions, whether or not identified in this communication and on the current expectations of MTAC\u2019s and TriSalus\u2019 respective managements and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.\n<\/p>\n \nMany factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of MTAC\u2019s securities; (ii) the risk that the Business Combination may not be completed by MTAC\u2019s business combination deadline and the potential failure to obtain an extension of the business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the stockholders of MTAC, the satisfaction of the minimum cash amount following any redemptions by MTAC\u2019s public stockholders, and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with the Business Combination; (vii) the effect of the announcement or pendency of the Business Combination on TriSalus\u2019 business relationships, operating results and business generally; (viii) risks that the Business Combination disrupts current plans and operations of TriSalus; (ix) the outcome of any legal proceedings that may be instituted against TriSalus or MTAC related to the Merger Agreement or the Business Combination; (x) the ability to maintain the listing of MTAC\u2019s securities on the Nasdaq; (xi) changes in business, market, financial, political and legal conditions; (xii) unfavorable changes in the reimbursement environment for TriSalus\u2019 products; (xiii) TriSalus\u2019 product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval, either on a timely basis or at all or subject to any conditions that negatively impact TriSalus\u2019 ability to commercialize the applicable product candidates; (xiv) TriSalus being unable to continue to grow TriNav\u00ae<\/sup> sales; (xv) the size of the addressable markets for TriNav\u00ae<\/sup> and SD-101, if successfully developed and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; (xvi) TriSalus\u2019 ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities; (xvii) TriSalus\u2019 ability to continue to fund preclinical and clinical trials for SD-101; (xviii) TriSalus\u2019 ability to partner with other companies; (xix) future economic and market conditions; (xx) the development, effects and enforcement of laws and regulations affecting TriSalus\u2019 business or industry; (xxi) TriSalus\u2019 ability to manage future growth; (xxii) TriSalus\u2019 ability to maintain and grow its market share; (xxiii) the effects of competition on TriSalus\u2019 business; (xxiv) the ability of MTAC or the combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future; (xxv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xxvi) costs related to the Business Combination; (xxvii) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions, including with respect to estimated stockholder redemptions; and (xxviii) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the \u201cRisk Factors\u201d section therein and in MTAC\u2019s other filings with the SEC. The foregoing list of factors is not exclusive. MTAC\u2019s other SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of MTAC, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of MTAC, TriSalus, or any of their respective representatives gives any assurance that either MTAC or TriSalus will achieve its expectations.\n<\/p>\n Participation in Solicitation<\/b><\/p>\n \nMTAC and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of MTAC\u2019s stockholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of MTAC\u2019s directors and officers in MTAC\u2019s filings with the SEC, including MTAC\u2019s registration statement on Form S-1, which was originally filed with the SEC on November 30, 2020, as amended, MTAC\u2019s 2021 Form 10-K, and the Registration Statement. To the extent that holdings of MTAC\u2019s securities have changed from the amounts reported in the Registration Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from MTAC\u2019s stockholders in connection with the Business Combination are included in the Registration Statement and will be set forth in the definitive proxy statement\/prospectus forming a part of the Registration Statement. Investors and security holders of MTAC and TriSalus are urged to carefully read in their entirety the proxy statement\/prospectus and other relevant documents that will be filed with the SEC, when they become available, because they will contain important information about the Business Combination.\n<\/p>\n \nInvestors and security holders will be able to obtain free copies of the proxy statement\/prospectus and other documents containing important information about MTAC and TriSalus through the website maintained by the SEC at www.sec.gov<\/a>. Copies of the documents filed with the SEC by MTAC can be obtained free of charge by directing a written request to MedTech Acquisition Corporation at 48 Maple Avenue, Greenwich, CT 06830.\n<\/p>\n \nINVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.\n<\/p>\n No Offer or Solicitation<\/b><\/p>\n \nThis communication shall not constitute an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230220005319\/en\/<\/a><\/span><\/p>\n<\/p>\n